HS Code:
The category 'Other, containing antimalarial active principles described in subheading note 2 to this chapter' under the Harmonized System (HS) Code pertains to pharmaceutical products or preparations that include active principles specifically used for the treatment of malaria. These products fall outside more specific classifications but are critical in global health initiatives targeting malaria-endemic regions. This category often includes a variety of formulations or compounds that are not classified under standard antimalarial drugs but still serve a therapeutic purpose in combating malaria.
Total Trade Volume
USD 320 million
Data from 2022
Source
United Nations Comtrade Database
USD 120 million
37.5% of total trade
Increasing
USD 80 million
25.0% of total trade
Stable
USD 50 million
15.6% of total trade
Increasing
USD 30 million
9.4% of total trade
Stable
USD 20 million
6.3% of total trade
Decreasing
Average Rate
5.2%
Highest Rate
12% (imposed by certain African nations to protect local industries)
Lowest Rate
0% (under preferential trade agreements like AGOA and EU GSP for least developed countries)
Increased demand for affordable antimalarial treatments
Driven by international health programs and funding from organizations like the Global Fund, demand has spurred production in low-cost manufacturing hubs like India and China.
2021-2022
Shift towards combination therapies
Growing preference for combination therapies to combat drug resistance has led to innovation in formulations within this category, impacting trade patterns.
2020-2022
Rising focus on local production in Africa
African nations are investing in domestic pharmaceutical capabilities, potentially reducing import dependency in the long term.
2022
The World Health Organization prequalified several new antimalarial active principles for use in endemic regions, boosting their credibility and market access.
March 2023
Expected to increase trade volumes as manufacturers scale up production to meet WHO procurement demands.
A new trade agreement has reduced tariffs on pharmaceutical products, including antimalarial principles, exported from India to African countries.
July 2023
Likely to solidify Indiaโs position as a leading exporter, potentially increasing its market share.
The European Union allocated โฌ50 million for research into novel antimalarial compounds, some of which fall under this HS category.
September 2022
May lead to increased innovation and trade of new products from European countries like Switzerland and Germany.